Generic: Aminophylline
Brand: Phyllocontin
(am- in- off'i- lin)
Exact mechanism unknown; relaxes smooth muscle of respiratory system by blocking phosphodiesterase, which increases cyclic AMP; increased cyclic AMP alters intracellular calcium ion movements; produces bronchodilatation, increased pulmonary blood flow, relaxation of respiratory tract
Therapeutic outcome: Increased ability to breathe
Apnea in infancy for respiratory/myocardial stimulation, bronchial asthma, bronchospasm associated with chronic bronchitis, emphysema Unlabeled uses: Methotrexate toxicity, sleep apnea, status asthmaticus
Hypersensitivity to xanthines, tachyhydrythmias
Precautions: Pregnancy C, breastfeeding, children, geriatric, CHF, cor pulmonale, hepatic disease, diabetes mellitus, hyperthyroidism, hypertension, seizure disorder, irritation of the rectum or lower colon, alcoholism, active peptic ulcer disease
Adult: PO 6 mg/kg, then 3 mg/kg q6 hr × 2 doses, then 3 mg/kg q8 hr maintenance, max 900 mg/day or 13 mg/kg; PO in CHF 6 mg/kg, then 2 mg/kg q8 hr × 2 doses, then 1- 2 mg/kg q12 hr maintenance; IV 4.7 mg/kg, then 0.55 mg/kg/hr × 12 hr, then 0.36 mg/kg/hr maintenance; IV in CHF 4.7 mg/kg, then 0.39 mg/kg/hr × 12 hr; then 0.08- 0.16 mg/kg/hr maintenance Geriatric and in cor pulmonale: PO 6 mg/kg, then 2 mg/kg q6 hr × 2 doses, then 2 mg/kg q8 hr maintenance; IV 4.7 mg/kg, then 0.47 mg/kg/hr × 12 hr, then 0.24 mg/kg/hr maintenance Child 9- 16 yr: PO 6 mg/kg, then 3 mg/kg q4 hr × 3 doses, then 3 mg/kg q6 hr maintenance, max 18 mg/kg/day 12- 16 yr, or 20 mg/kg/day 9- 12 yr; IV 4.7 mg/kg, then 0.79 mg/kg/hr × 12 hr, then 0.63 mg/kg/hr maintenance Child 6 mo- 9 yr: PO 4 mg/kg q4 hr × 3 doses, then 4 mg/kg q6 hr maintenance, max 24 mg/kg day; IV 4.7 mg/kg, then 0.95 mg/kg/hr × 12 hr, then 0.79 mg/kg/hr maintenance Infant 6- 52 wk: Dose (0.2× age in wk) \div 5 × kg = 24 hr dose in mg Neonate up to 40 wk premature postconception age: PO/IV 1 mg/kg q12 hr Neonate at birth or 40 wk postconception age: PO/IV >8 wk postnatal 1- 3 mg/kg q6 hr; 4- 8 wk postnatal 1- 2 mg/kg q8 hr; up to 4 wk postnatal 1- 2 mg/kg q12 hr Hepatic disease
Adult: PO 6 mg/kg, then 2 mg/kg q8 hr × 2 doses, then 1- 2 mg/kg q12 hr maintenance; IV 4.7 mg/kg, then 0.39 mg/kg/hr × 12 hr, then 0.08- 0.16 mg/kg/hr maintenance
Available forms: Inj 250 mg/10 ml, 500 mg/20 ml, 100 mg/100 ml in 0.45% NaCl; 200 mg/100 ml in 0.45% NaCl; rectal supp 250 mg, 500 mg; oral liq 105 mg/5 ml; tabs 100, 200 mg; cont rel tabs 225, 350 mg
Implementation Give around the clock to maintain blood (theophylline) levels If switching from IV to PO, give controlled- release dose at time IV infusion is discontinued; if giving tab (immediate release), discontinue IV and wait >4 hr If GI upset occurs, take with 8 oz of water or food Increase fluids to 2 L/day
PO route: Do not break, crush, or chew enteric- coated or cont rel tabs Avoid giving with food
Continuous IV infusion route: May be diluted for IV inf in 100- 200 ml in D_{5}W D_{10}W D_{20}W 0.9% NaCl, 0.45% NaCl, LR Give loading dose over \frac{1}{2} hr, max rate of inf 25 mg/min, use infusion pump; after loading dose, give by cont inf Avoid IM inj; pain and tissue damage may occur Only clear sol; flush IV line before dose; store diluted sol for 24 hr if refrigerated
Syringe compatibilities: Heparin, metoclopramide, PENTobarbital, thiopental
Y- site compatibilities: Allopurinol, amifestone, amphotericin B sulfate complex, in- amrinone, aztreonam, cefTAZidine, cimetidine, cladribine, DOXOrubicin liposome, enalaprilat, esmolol, famotidine, filgrastim, fluconazole, fludarabine, foscarnet, gallium, granisetron, heparin sodium with hydrocortisone sodium succinate, labetalol, melphalan, meropenem, netilmicin, PAClitaxel, pancuronium, piperacillin/tazobactam, potassium chloride, propofol, ranitidine, remifentanil, sargramostim, tacrolimus, teniposide, thiotepa, tolazoline, vecuronium Y- site incompatibilities: DOBUTamine, hydrALAZINE, ondansetron
CNS: Anxiety, restlessness, insomnia, dizzyness, seizures, headache, light- headedness, muscle twitching, tremors
CV: Palpitations, sinus tachycardia, hypotension, flushing, dysrhythmias, edema
GI: Nausea, vomiting, diarrhea, dyspepsia, anal irritation (suppositories), epigastric pain, reflux, anorexia
GU: Urinary frequency, SIADH
INTEG: Flushing, urticaria
MISC: Hyperglycemia
RESP: Tachypnea, increased respiratory rate
Absorption: Well absorbed (PO), slow (PO–EXT REL), erratic (RECT)
Distribution: Widely distributed; crosses placenta
Metabolism: Liver to caffeine
Excretion: Kidneys
Half-life: 3-12 hr, increased in renal disease, CHF, geriatric patients, smokers, crosses into CSF (cerebrospinal fluid)
Onset: 15-60 min (PO), Unknown (PO-EXT), Immediate (IV)
Peak: 1-2 hr (PO), 4-7 hr (PO-EXT), Infusion's end (IV)
Duration: 6-8 hr (PO), 8-12 hr (PO-EXT), 6-8 hr (IV)
Individual drugs Allopurinol (high doses), cimetidine, clarithromycin, disulfiram, erythromycin, fluvoxamine, interferon, mexiletine: decreased metabolism, increased toxicity of aminophylline CarBAMazepine, isoniazid: increased or decreased aminophylline levels
Halothane: increased risk of dysrhythmias Ketoconazole, phenytoin, rifampin: decreased aminophylline effect
Lithium: decreased effect of lithium
Smoking: increased metabolism, decreased effect
Drug classifications Barbiturates, \beta - adrenergic blockers: decreased effect of aminophylline Benzodiazepines, \beta - blockers (nonselective), corticosteroids, diuretics (loop), fluoroquinolones, influenza vaccines, oral contraceptives: increased aminophylline levels Corticosteroids, influenza vaccines: increased aminophylline toxicity Diuretics (loop): may increase or decrease aminophylline levels Dose- dependent reversal of neuromuscular blockade
Fluoroquinolones: decreased metabolism, increased toxicity
Sympathomimetics: increased CNS, CV adverse reactions
Tetracyclines: increased adverse reactions
Drug/herb Cola tree, ginseng, guarana, horsetail, Siberian ginseng, tea (black, green), yerba mate: increased effects St. John's wort: decreased effects
Drug/food High- carbohydrate, low- protein diet: decreased elimination Low- carbohydrate, high- protein diet, charcoal- broiled beef: increased elimination
Xanthines: increased effect
Drug/lab test
Increased: plasma free fatty acids
Assessment Monitor theophylline blood levels (therapeutic level is 10 - 20 mg/ml ); toxicity may occur with small increase above 20 mg/ml , especially geriatric; determine whether theophylline was given recently (24 hr); check for toxicity: nausea, vomiting, anxiety, restlessness, insomnia, tachycardia, dysrhythmias, seizures; notify prescriber immediately Monitor I&O; diuresis will occur; dehydration may result in geriatric or children in whom diuresis is great Monitor liver function tests: periodically, lower doses may be required in those with moderate to severe hepatic disease Monitor respiratory rate, rhythm, depth; auscultate lung fields bilaterally, pulmonary function tests; notify prescriber of abnormalities; check ECG for tachycardia, PVCs, PACs in patients with cardiac problems Monitor allergic reactions: rash, urticaria; if these occur, product should be discontinued, prescriber notified
Patient/family education Teach patient to take doses as prescribed, not to skip dose; to check OTC medications, current prescription medications for ephedrine, which will increase CNS stimulation; advise patient not to drink alcohol or caffeine products (tea, coffee, chocolate, colas), which will increase action Teach patient to avoid hazardous activities; dizziness may occur Teach patient if GI upset occurs, to take product with 8 oz of water or food; absorption may be decreased Teach patient to remain in bed 15-20 min after rect supp is inserted to prevent removal Instruct patient to avoid smoking because it increases metabolism; decreases blood levels and terminal half-life; dosage may need to be increased Teach patient to obtain blood levels of product every few months to prevent toxicity; not to change brands, since effect may not be the same Teach patient to increase fluids to 2 L/day to decrease viscosity of secretions Advise patient to report toxicity: nausea, vomiting, anxiety, insomnia, rapid pulse, seizures, flushing, headache, diarrhea
Evaluation
Positive therapeutic outcome: Decreased dyspnea; Respiratory stimulation in infants; Clear lung fields bilaterally
Save notes, bookmark this drug, and run formula method dosage calculations all inside the KosPharm Dashboard.
Sign in to Continue